Association between expression of human papillomavirus 16/18 E6 oncoprotein and survival in patients with stage I non-small cell lung cancer

Nan Yung Hsu, Ya Wen Cheng, I. Ping Chan, Heng Chien Ho, Chih Yi Chen, Chung Ping Hsu, Meng Hung Lin, Ming Chih Chou

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The clinical significance of HPV-16/18 E6 oncoprotein expression in non-small cell lung cancer (NSCLC) is not fully known. A study was undertaken to investigate the association between expression of human papillomavirus 16/18 E6 oncoprotein and survival in patients with stage I NSCLC. We analyzed a series of 217 patients with stage I NSCLC for the presence of HPV-16/18 E6 oncoprotein by immunohistochemistry. HPV-16 E6 onco-protein was expressed in 49 (22.6%) patients and HPV-18 E6 oncoprotein was expressed in 31 (14.3%) patients. Statistical analysis revealed that the prevalence of expression of HPV-16 and HPV-18 E6 oncoproteins was significantly high in female patients, nonsmokers and patients with adenocarcinoma. The adjusted odds ratio for expression of HPV-16 E6 oncoprotein in female patients was 2.275 [95% confidence interval (CI), 0.999-5.179] and that in patients with adenocarcinoma was 2.320 (95% CI, 1.029-5.232). These ratios were significantly higher than those in male patients and patients with squamous cell carcinoma. Interestingly, we found that the 17 patients who expressed HPV-16 and HPV-18 E6 oncoprotein had a higher 5-year cumulate survival rate (72.2%) than the 154 patients who did not express both oncoproteins (48.3%); the difference was significant (p=0.055). Expression of HPV-16/18 E6 oncoprotein in stage I NSCLC may play an important role in female adenocarcinoma patients and survival benefits in patients who expressed HPV-16 and HPV-18 E6 oncoprotein.

Original languageEnglish
Pages (from-to)81-87
Number of pages7
JournalOncology Reports
Volume21
Issue number1
DOIs
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

Human papillomavirus 18
Human papillomavirus 16
Oncogene Proteins
Non-Small Cell Lung Carcinoma
Survival
Adenocarcinoma
Confidence Intervals
Human papillomavirus type 18 E6 protein

Keywords

  • Human papillomavirus
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Association between expression of human papillomavirus 16/18 E6 oncoprotein and survival in patients with stage I non-small cell lung cancer. / Hsu, Nan Yung; Cheng, Ya Wen; Chan, I. Ping; Ho, Heng Chien; Chen, Chih Yi; Hsu, Chung Ping; Lin, Meng Hung; Chou, Ming Chih.

In: Oncology Reports, Vol. 21, No. 1, 2009, p. 81-87.

Research output: Contribution to journalArticle

Hsu, Nan Yung ; Cheng, Ya Wen ; Chan, I. Ping ; Ho, Heng Chien ; Chen, Chih Yi ; Hsu, Chung Ping ; Lin, Meng Hung ; Chou, Ming Chih. / Association between expression of human papillomavirus 16/18 E6 oncoprotein and survival in patients with stage I non-small cell lung cancer. In: Oncology Reports. 2009 ; Vol. 21, No. 1. pp. 81-87.
@article{64014c9852c141bf8dc1195e7bed1a84,
title = "Association between expression of human papillomavirus 16/18 E6 oncoprotein and survival in patients with stage I non-small cell lung cancer",
abstract = "The clinical significance of HPV-16/18 E6 oncoprotein expression in non-small cell lung cancer (NSCLC) is not fully known. A study was undertaken to investigate the association between expression of human papillomavirus 16/18 E6 oncoprotein and survival in patients with stage I NSCLC. We analyzed a series of 217 patients with stage I NSCLC for the presence of HPV-16/18 E6 oncoprotein by immunohistochemistry. HPV-16 E6 onco-protein was expressed in 49 (22.6{\%}) patients and HPV-18 E6 oncoprotein was expressed in 31 (14.3{\%}) patients. Statistical analysis revealed that the prevalence of expression of HPV-16 and HPV-18 E6 oncoproteins was significantly high in female patients, nonsmokers and patients with adenocarcinoma. The adjusted odds ratio for expression of HPV-16 E6 oncoprotein in female patients was 2.275 [95{\%} confidence interval (CI), 0.999-5.179] and that in patients with adenocarcinoma was 2.320 (95{\%} CI, 1.029-5.232). These ratios were significantly higher than those in male patients and patients with squamous cell carcinoma. Interestingly, we found that the 17 patients who expressed HPV-16 and HPV-18 E6 oncoprotein had a higher 5-year cumulate survival rate (72.2{\%}) than the 154 patients who did not express both oncoproteins (48.3{\%}); the difference was significant (p=0.055). Expression of HPV-16/18 E6 oncoprotein in stage I NSCLC may play an important role in female adenocarcinoma patients and survival benefits in patients who expressed HPV-16 and HPV-18 E6 oncoprotein.",
keywords = "Human papillomavirus, Non-small cell lung cancer",
author = "Hsu, {Nan Yung} and Cheng, {Ya Wen} and Chan, {I. Ping} and Ho, {Heng Chien} and Chen, {Chih Yi} and Hsu, {Chung Ping} and Lin, {Meng Hung} and Chou, {Ming Chih}",
year = "2009",
doi = "10.3892/or_00000192",
language = "English",
volume = "21",
pages = "81--87",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Association between expression of human papillomavirus 16/18 E6 oncoprotein and survival in patients with stage I non-small cell lung cancer

AU - Hsu, Nan Yung

AU - Cheng, Ya Wen

AU - Chan, I. Ping

AU - Ho, Heng Chien

AU - Chen, Chih Yi

AU - Hsu, Chung Ping

AU - Lin, Meng Hung

AU - Chou, Ming Chih

PY - 2009

Y1 - 2009

N2 - The clinical significance of HPV-16/18 E6 oncoprotein expression in non-small cell lung cancer (NSCLC) is not fully known. A study was undertaken to investigate the association between expression of human papillomavirus 16/18 E6 oncoprotein and survival in patients with stage I NSCLC. We analyzed a series of 217 patients with stage I NSCLC for the presence of HPV-16/18 E6 oncoprotein by immunohistochemistry. HPV-16 E6 onco-protein was expressed in 49 (22.6%) patients and HPV-18 E6 oncoprotein was expressed in 31 (14.3%) patients. Statistical analysis revealed that the prevalence of expression of HPV-16 and HPV-18 E6 oncoproteins was significantly high in female patients, nonsmokers and patients with adenocarcinoma. The adjusted odds ratio for expression of HPV-16 E6 oncoprotein in female patients was 2.275 [95% confidence interval (CI), 0.999-5.179] and that in patients with adenocarcinoma was 2.320 (95% CI, 1.029-5.232). These ratios were significantly higher than those in male patients and patients with squamous cell carcinoma. Interestingly, we found that the 17 patients who expressed HPV-16 and HPV-18 E6 oncoprotein had a higher 5-year cumulate survival rate (72.2%) than the 154 patients who did not express both oncoproteins (48.3%); the difference was significant (p=0.055). Expression of HPV-16/18 E6 oncoprotein in stage I NSCLC may play an important role in female adenocarcinoma patients and survival benefits in patients who expressed HPV-16 and HPV-18 E6 oncoprotein.

AB - The clinical significance of HPV-16/18 E6 oncoprotein expression in non-small cell lung cancer (NSCLC) is not fully known. A study was undertaken to investigate the association between expression of human papillomavirus 16/18 E6 oncoprotein and survival in patients with stage I NSCLC. We analyzed a series of 217 patients with stage I NSCLC for the presence of HPV-16/18 E6 oncoprotein by immunohistochemistry. HPV-16 E6 onco-protein was expressed in 49 (22.6%) patients and HPV-18 E6 oncoprotein was expressed in 31 (14.3%) patients. Statistical analysis revealed that the prevalence of expression of HPV-16 and HPV-18 E6 oncoproteins was significantly high in female patients, nonsmokers and patients with adenocarcinoma. The adjusted odds ratio for expression of HPV-16 E6 oncoprotein in female patients was 2.275 [95% confidence interval (CI), 0.999-5.179] and that in patients with adenocarcinoma was 2.320 (95% CI, 1.029-5.232). These ratios were significantly higher than those in male patients and patients with squamous cell carcinoma. Interestingly, we found that the 17 patients who expressed HPV-16 and HPV-18 E6 oncoprotein had a higher 5-year cumulate survival rate (72.2%) than the 154 patients who did not express both oncoproteins (48.3%); the difference was significant (p=0.055). Expression of HPV-16/18 E6 oncoprotein in stage I NSCLC may play an important role in female adenocarcinoma patients and survival benefits in patients who expressed HPV-16 and HPV-18 E6 oncoprotein.

KW - Human papillomavirus

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=61449428431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449428431&partnerID=8YFLogxK

U2 - 10.3892/or_00000192

DO - 10.3892/or_00000192

M3 - Article

C2 - 19082446

AN - SCOPUS:61449428431

VL - 21

SP - 81

EP - 87

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1

ER -